Takeda and Lundbeck’s Trintellix (vortioxetine) Receives MHLW’s Approval for Major Depressive Disorder in Japan

 Takeda and Lundbeck’s Trintellix (vortioxetine) Receives MHLW’s Approval for Major Depressive Disorder in Japan

Takeda and Lundbeck’s Trintellix (vortioxetine) Receives MHLW’s Approval for Major Depressive Disorder in Japan

Shots:

  • The MHLW’s approval follows P-III study (NCT02389816) assessing Trintellix (10mg/20mg) vs PBO in 493 patients with recurrent depression in Japan which demonstrated improvement in overall symptoms of depression in adults
  • The NDA submission also follows other three pivotal studies conducted globally (NCT01255787) and in Japan (NCT01355081, NCT01395147), submitted on Sept’2018. In 2007, the companies collaborated to co-develop & co-commercialize Trintellix in Japan
  • Trintellix is a serotonin reuptake inhibitor, regulating neurotransmission via serotonin, norepinephrine, dopamine, acetylcholine and histamine and is an approved therapy in 83 countries including the US, EU and other countries

Click here to­ read full press release/ article | Ref: Takeda | Image: Hines

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post